Eton Pharmaceuticals (ETON) Stock Price, News & Analysis

$3.25
+0.06 (+1.88%)
(As of 04/22/2024 ET)
Today's Range
$3.19
$3.34
50-Day Range
$3.06
$4.59
52-Week Range
$2.42
$5.81
Volume
39,976 shs
Average Volume
68,466 shs
Market Capitalization
$83.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Eton Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
207.7% Upside
$10.00 Price Target
Short Interest
Healthy
0.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.39 out of 5 stars

Medical Sector

482nd out of 910 stocks

Pharmaceutical Preparations Industry

218th out of 426 stocks

ETON stock logo

About Eton Pharmaceuticals Stock (NASDAQ:ETON)

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

ETON Stock Price History

ETON Stock News Headlines

Eton Pharma Buys U.S. Rights To PKU GOLIKE From Relief Therapeutics
Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
ETON Apr 2024 5.000 call
Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
Recap: Eton Pharmaceuticals Q4 Earnings
Q4 2023 Eton Pharmaceuticals Inc Earnings Call
Eton Pharmaceuticals Earnings Preview
Eton Pharmaceuticals earnings preview: what Wall Street is expecting
See More Headlines
Receive ETON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
4/22/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ETON
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+207.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-940,000.00
Pretax Margin
-2.18%

Debt

Sales & Book Value

Annual Sales
$31.64 million
Book Value
$0.60 per share

Miscellaneous

Free Float
22,307,000
Market Cap
$83.49 million
Optionable
Optionable
Beta
1.17
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

ETON Stock Analysis - Frequently Asked Questions

Should I buy or sell Eton Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ETON shares.
View ETON analyst ratings
or view top-rated stocks.

What is Eton Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued 1 year target prices for Eton Pharmaceuticals' shares. Their ETON share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 207.7% from the stock's current price.
View analysts price targets for ETON
or view top-rated stocks among Wall Street analysts.

How have ETON shares performed in 2024?

Eton Pharmaceuticals' stock was trading at $4.38 at the start of the year. Since then, ETON shares have decreased by 25.8% and is now trading at $3.25.
View the best growth stocks for 2024 here
.

Are investors shorting Eton Pharmaceuticals?

Eton Pharmaceuticals saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 220,400 shares, a decline of 9.3% from the March 15th total of 242,900 shares. Based on an average daily volume of 70,600 shares, the short-interest ratio is presently 3.1 days. Approximately 1.0% of the company's shares are sold short.
View Eton Pharmaceuticals' Short Interest
.

When is Eton Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ETON earnings forecast
.

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) issued its earnings results on Thursday, March, 14th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.05. The company earned $7.31 million during the quarter, compared to analyst estimates of $7.70 million. Eton Pharmaceuticals had a negative net margin of 2.96% and a negative trailing twelve-month return on equity of 6.21%.

What other stocks do shareholders of Eton Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA).

When did Eton Pharmaceuticals IPO?

Eton Pharmaceuticals (ETON) raised $22 million in an IPO on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation acted as the underwriter for the IPO.

Who are Eton Pharmaceuticals' major shareholders?

Eton Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Westside Investment Management Inc. (2.23%). Insiders that own company stock include Opaleye Management Inc, Pharmaceutical Co Ltd Takeda and Sean Brynjelsen.
View institutional ownership trends
.

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ETON) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners